Chicago Capital LLC Has $34.96 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Chicago Capital LLC reduced its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 970,607 shares of the medical device company’s stock after selling 32,540 shares during the quarter. Chicago Capital LLC’s holdings in Tandem Diabetes Care were worth $34,961,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. KBC Group NV grew its position in shares of Tandem Diabetes Care by 41.5% during the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company’s stock worth $6,933,000 after buying an additional 56,461 shares during the period. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $92,000. Janney Montgomery Scott LLC grew its position in shares of Tandem Diabetes Care by 17.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 30,240 shares of the medical device company’s stock valued at $1,089,000 after purchasing an additional 4,412 shares during the period. LVW Advisors LLC grew its position in shares of Tandem Diabetes Care by 13.8% in the 4th quarter. LVW Advisors LLC now owns 7,798 shares of the medical device company’s stock valued at $281,000 after purchasing an additional 944 shares during the period. Finally, Park Avenue Securities LLC grew its position in shares of Tandem Diabetes Care by 34.5% in the 4th quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company’s stock valued at $321,000 after purchasing an additional 2,286 shares during the period.

Tandem Diabetes Care Trading Up 0.1 %

TNDM opened at $37.06 on Monday. Tandem Diabetes Care, Inc. has a 1-year low of $21.85 and a 1-year high of $53.69. The stock’s fifty day simple moving average is $34.85 and its 200 day simple moving average is $37.37. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The firm’s revenue for the quarter was up 31.4% on a year-over-year basis. Equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the director now directly owns 195,190 shares of the company’s stock, valued at $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 2.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TNDM shares. Morgan Stanley upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a research report on Monday, December 2nd. Canaccord Genuity Group decreased their price objective on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Sanford C. Bernstein started coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price target for the company. Citigroup reduced their price target on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Robert W. Baird reduced their price target on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and a consensus price target of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.